Nintedanib Eignapharma (Nintedanib)

Nintedanib Eignapharma acts on multiple receptor tyrosine kinases that drive fibrotic and oncogenic pathways. It is clinically employed for the following conditions:

• Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function.
• Systemic sclerosis‑associated interstitial lung disease: limits fibrotic remodeling and preserves respiratory capacity.
• Non‑small cell lung cancer (in combination with docetaxel): enhances anti‑tumour efficacy and improves survival outcomes.

• Nintedanib inhibits the intracellular kinase activity of vascular endothelial growth factor receptors (VEGFR 1‑3), platelet‑derived growth factor receptors (PDGFR α/β) and fibroblast growth factor receptors (FGFR 1‑3). By blocking these pathways, it reduces fibroblast proliferation, migration, and transformation, and also exerts anti‑angiogenic effects that limit tumour vascularisation and fibrotic tissue development.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhoea: frequent loose stools, often early in treatment.
• Decreased appetite: reduced desire to eat.
• Abdominal pain: discomfort or cramps in the stomach area.
• Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects

• Hepatic failure: signs of severe liver injury.
• Severe bleeding: gastrointestinal or intracranial haemorrhage.
• Arterial thromboembolism: clot formation in arteries.
• Severe hypertension: markedly high blood pressure.
• Perforation of the gastrointestinal tract: rare but life‑threatening.

Before initiating therapy, clinicians should evaluate several safety aspects.

• Liver monitoring: perform baseline and periodic liver function tests.
• Bleeding risk: assess for anticoagulant use or bleeding disorders.
• Cardiovascular assessment: check blood pressure and history of arterial events.
• Pregnancy avoidance: drug is contraindicated in pregnancy (Category D).
• Hepatic impairment dose adjustment: consider reduced exposure in severe liver disease.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
• Potent P‑gp inhibitors (e.g., verapamil): can raise plasma concentrations.
• Concurrent use of other anti‑angiogenic agents: heightens risk of bleeding and hypertension.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors or inducers (e.g., fluconazole, rifampicin): may modestly alter drug levels.
• Antacids or proton‑pump inhibitors: could affect absorption if taken simultaneously.
• Diuretics: monitor electrolytes and renal function.
• Anticoagulants (e.g., warfarin): observe for increased bleeding tendency.